Skip to Main Content

Advertisement

Skip Nav Destination

FDA Approval Summary: Pemigatinib for Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma with FGFR2 Fusion or Other Rearrangement

Clin Cancer Res OF1–OF5.
Currently there are no citedby results. Try again later.
Close Modal

or Create an Account

Close Modal
Close Modal